To officially welcome Prof. Valenzuela to the Editorial Board and get to know him a little better, we invited him to reflect on what drew him to dermatology, the career experiences he has valued most, the advances that have transformed patient care and the innovations he hopes to see in the future. He also shares what he is most looking forward to in his new role with touchREVIEWS in Dermatology and the small things that brighten a busy working day.

The treatment landscape for vitiligo is evolving, with recent therapeutic advances, potential oral treatments, combination strategies and new consensus efforts helping to shape future care. In this expert interview, Prof. Viktoria Eleftheriadou discusses key takeaways from her BAD Annual Meeting session, including emerging systemic therapies, approaches to improving repigmentation outcomes and the importance of defining vitiligo severity beyond body surface area alone.

More than 35% of patients receiving zasocitinib achieved complete skin clearance, more than 2.5 times the response rate observed with deucravacitinib. [touchplayvideo video_id="mh592ao0iz"] In this video, we speak with Dr Linda Stein Gold (Henry Ford Health, Detroit, MI, ...

Targeting IL-36 signaling, imsidolimab significantly improved clear or almost clear skin responses at Week 4 compared with placebo in patients experiencing a generalized pustular psoriasis flare, with monthly maintenance treatment supporting sustained responses through 24 weeks.

From adjuvant immunotherapy in Merkel cell carcinoma to cellular therapy in advanced melanoma, late-breaking ASCO data offer new insights into evolving treatment strategies for difficult-to-treat skin cancers.

Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our LEADderm mini-series exploring non-clinical skills that can help you thrive in your ...

Zumilokibart met its primary and key secondary endpoints in the phase 2 APEX trial, with 65.9% of patients receiving the mid-dose regimen achieving EASI-75 at Week 16 compared with 23.4% receiving placebo. The results support advancement into phase 3 development in moderate-to-severe atopic dermatitis, with studies planned for the second half of 2026.

As he joins the touchREVIEWS in Dermatology Editorial Board, Dr Jonathan Ho reflects on training the next generation, improving care for patients with richly pigmented skin, and bringing Caribbean perspectives to global dermatology.

Selected abstracts from ESCMID Global 2026 highlight findings relevant to infectious dermatology and wound care, including cutaneous infection, wound complications, fungal disease, and inflammatory dermatoses. The article spans randomized clinical data, early-stage therapeutic research, and diagnostic case reports.